Prezzo SBP GROUP 01177.HK

Sino Biopharmaceutical Limited (“the Company” or “Sino Biopharmaceutical”) and its subsidiaries (“the Group”) are a leading innovation- and R&D-driven pharmaceutical group in China, with operations spanning the entire value chain from drug development and smart manufacturing to commercial sales. Its products cover a wide range of biologic and chemical drugs, and the Group holds leading positions in four core therapeutic areas: oncology, liver disease/cardiovascular and metabolic diseases, respiratory diseases/autoimmune diseases, and surgery/analgesia. The Company was listed on the Hong Kong Stock Exchange in 2000; in 2013, it was selected as a constituent stock of the China Index in the MSCI Global Standard Indexes; in 2018, it was selected as a constituent stock of the Hang Seng Index; and in 2020, it was selected as a constituent stock of the Hang Seng Shanghai-Shenzhen-Hong Kong Stock Connect Biotechnology 50 Index and the Hang Seng China (Hong Kong-listed) 25 Index. It was listed among the “Global Pharma Top 50” published by the authoritative U.S. magazine Pharmaceutical Executive for seven consecutive years, and was named one of Forbes Asia’s “50 Best Companies in the Asia-Pacific” for three consecutive years. The Group’s companies are located in Beijing, Shanghai, Nanjing, Lianyungang, and other locations, and it owns multiple pharmaceutical production bases. Since its establishment, the Group has continued to achieve outstanding results and steady growth. Its core member companies include Chia Tai Tianqing Pharmaceutical Group Co., Ltd. (“Chia Tai Tianqing”), Beijing Tide Pharmaceutical Co., Ltd. (“Beijing Tide”), Laekna Therapeutics (Shanghai) Co., Ltd. (“Laekna”), Hangzhou Hegia Biopharmaceutical Co., Ltd. (“Hegia”), Nanjing Chia Tai Tianqing Pharmaceutical Co., Ltd. (“Nanjing Tianqing”), Jiangsu Chia Tai Qingjiang Pharmaceutical Co., Ltd. (“Chia Tai Qingjiang”), Jiangsu Chia Tai Fenghai Pharmaceutical Co., Ltd. (“Chia Tai Fenghai”), and invoX Pharma Limited (“invoX”). Guided by its mission of “Health Technology, Bringing Warmth to More Lives,” Sino Biopharmaceutical focuses on innovation, serves patients, and is committed to becoming a leading global pharmaceutical company.